Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Genovese

Showing results (41-50 of 172) with videos related to

Pageof 18
Sort By:
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 23, 2022
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysisXavier Montalban, Daniel Wallace, Mark C Genovese, et al.
Annals of the Rheumatic Diseases|June 25, 2016
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritisGerd R Burmester, Robert Landewé, Mark C Genovese, et al.
Neurodegenerative Disease Management|June 22, 2023
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosisXavier Montalban, Daniel Wallace, Mark C Genovese, et al.
The Journal of Rheumatology|February 5, 2013
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trialMichael E Weinblatt, Arthur Kavanaugh, Mark C Genovese, et al.
The Journal of Rheumatology|April 3, 2013
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging StudyWilliam Stohl, Joan T Merrill, James D McKay, et al.
Annals of the Rheumatic Diseases|April 20, 2013
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexateMark C Genovese, Eric Lee, Julie Satterwhite, et al.
Annals of the Rheumatic Diseases|July 31, 2014
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapyPeter C Taylor, Mark C Genovese, Mike Greenwood, et al.
Annals of the Rheumatic Diseases|May 5, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateStanley B Cohen, Edward Keystone, Mark C Genovese, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 10, 2017
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid ArthritisMark C Genovese, Joel M Kremer, Ronald F van Vollenhoven, et al.
Pageof 18

Showing results (41-50 of 172) with videos related to

Sort By:
Pageof 18
European Journal of Rheumatology|June 8, 2021
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studiesMark C Genovese, Patrick Durez, Roy Fleischmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 23, 2022
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysisXavier Montalban, Daniel Wallace, Mark C Genovese, et al.
Annals of the Rheumatic Diseases|June 25, 2016
Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritisGerd R Burmester, Robert Landewé, Mark C Genovese, et al.
Neurodegenerative Disease Management|June 22, 2023
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosisXavier Montalban, Daniel Wallace, Mark C Genovese, et al.
The Journal of Rheumatology|February 5, 2013
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trialMichael E Weinblatt, Arthur Kavanaugh, Mark C Genovese, et al.
The Journal of Rheumatology|April 3, 2013
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging StudyWilliam Stohl, Joan T Merrill, James D McKay, et al.
Annals of the Rheumatic Diseases|April 20, 2013
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexateMark C Genovese, Eric Lee, Julie Satterwhite, et al.
Annals of the Rheumatic Diseases|July 31, 2014
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapyPeter C Taylor, Mark C Genovese, Mike Greenwood, et al.
Annals of the Rheumatic Diseases|May 5, 2010
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexateStanley B Cohen, Edward Keystone, Mark C Genovese, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 10, 2017
Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid ArthritisMark C Genovese, Joel M Kremer, Ronald F van Vollenhoven, et al.
Pageof 18